|
|
Strategic Navigators

Ulcerative Colitis Target Patient Analysis

Pages: 94
Published: August 2022
Individual License: $4,950
Team License: $5,950
ulcerative colitis target patient, UC target patient, UC patient information, ulcerative colitis ideal patient, ulcerative colitis market research

Ulcerative Colitis Target Patient Analysis breaks down the unique aspects of eight branded UC products amongst UC patients. The Ulcerative Colitis Target Patient Analysis of each drug differ from one another, but some also share similarities among surveyed gastroenterologists. The report describes those differences and each brand’s unique emotional perceptions. 

Between disease severity, treatment history, lifestyle choices, and much more, UC patients will have different perspectives on treatment options and the brands that coincide with those. As newly launched brands and pipeline treatments try to understand and work with the target UC patient, it’s helpful to understand the backgrounds of those patients and their perceptions of each existing brand. 

Multiple categories make up the ‘typical’ UC patient. This report shows how each brand preforms with different types of UC patients and how the patient population is broken down based on their unique needs. With a thorough analysis of the UC patient market that highlights key aspects of patients and how they make decisions, this report is an invaluable tool to inform your ulcerative colitis brand’s launch strategy, marketing plan or communications playbook

Overview of Ulcerative Colitis Patient Analysis

US gastroenterologists approach each ulcerative colitis brand differently depending on a set of patient characteristics. Ulcerative Colitis Target Patient Analysis shows how each gastroenterologist and UC patient decide which branded ulcerative colitis medication is best for their unique situation. These UC patient aspects give insight into why gastroenterologists make their treatment decisions.

The report focuses on how US gastroenterologists’ and UC patients react to branded UC medications based on details in a patient’s life such as:

  • Disease severity
  • Treatment history
  • Lifestyle
  • Adherence
  • Comorbidities

Branded Treatments Analyzed

  • Entyvio
  • Humira
  • Remicade
  • Simponi
  • Stelara
  • Uceris
  • Xeljanz
  • Zeposia

Strategic Questions Answered about Ulcerative Colitis Target Patient Analysis

  • Treatment Drivers: What are the key patient characteristics that drive HCP prescription decisions among UC treatments?
  • Brand Ownership: What characteristics define the ‘typical’ patient receiving current UC treatments?
  • Patient Segments: What are the most common UC patient archetypes that shape how HCPs make prescription decisions?

Summary of Strategic Insights around Ulcerative Colitis Target Patient Analysis

  • For patients who need a new UC treatment either because their disease has progressed to a moderate to severe state or because they have failed a biologic, Entyvio is a near-ideal solution.
  • Oral therapies Xeljanz and Zeposia provide HCPs with an oral medication for moderate UC patients who have failed at least one biologic and who have no comorbidities.
  • Humira continues to provide Gastros with a frequently used first-line option to treat moderate UC patients who lead a very active lifestyle but have yet to try a biologic treatment.

Benefits of Purchasing Ulcerative Colitis Target Patient Analysis

  • Cost-efficient analysis about UC patient trends to support your strategic marketing decisions.
  • Insights drawn from in-depth interviews among global KOLs and surveys of more than 125 gastroenterologists
  • A complimentary 30-minute workshop with you (and your team)
  • Unlimited support from Vivisum’s ulcerative colitis strategist for 1-year.

Table of Contents

Executive Summary – 6
  • Research Methodology: Robust Insights from US Gastroenterologists – 7
  • The Strategic Six: Key Insights About Target Patients for UC Brands – 8
  • ‘Typical’ Patient Map – 9
UC Brand Target Patient Profiles – 10
  • Patient Share by Ulcerative Colitis Treatment – 11
  • 12-month Prescribing Trends – 12
    Entyvio Patient Profile – 13
    • Entyvio ‘Typical’ Patient Summary – 14
    • Entyvio Patient ‘Typical’ Disease Severity – 15
    • Entyvio Patient ‘Typical’ Treatment History – 16
    • Entyvio Patient: ‘Typical’ Lifestyle – 17
    • Entyvio Patient: ‘Typical’ Treatment Adherence – 18
    • Entyvio Patient: ‘Typical’ Comorbidities – 19
    Remicade Patient Profile – 13
    • Remicade Patient ‘Typical’ Disease Severity – 22
    • Remicade Patient ‘Typical’ Treatment History – 23
    • Remicade Patient: ‘Typical’ Lifestyle – 24
    • Remicade Patient: ‘Typical’ Treatment Adherence – 25
    • Remicade Patient: ‘Typical’ Comorbidities – 26
    Humira Patient Profile – 27
    • Humira ‘Typical’ Patient Summary – 28
    • Humira Patient ‘Typical’ Disease Severity – 29
    • Humira Patient ‘Typical’ Treatment History – 30
    • Humira Patient: ‘Typical’ Lifestyle – 31
    • Humira Patient: ‘Typical’ Treatment Adherence – 32
    • Humira Patient: ‘Typical’ Comorbidities – 33
    Stelara Patient Profile – 34
    • Stelara ‘Typical’ Patient Summary – 35
    • Stelara Patient ‘Typical’ Disease Severity – 36
    • Stelara Patient ‘Typical’ Treatment History – 37
    • Stelara Patient: ‘Typical’ Lifestyle – 38
    • Stelara Patient: ‘Typical’ Treatment Adherence – 39
    • Stelara Patient: ‘Typical’ Comorbidities – 40
    Uceris Patient Profile – 41
    • Uceris ‘Typical’ Patient Summary – 42
    • Uceris Patient ‘Typical’ Disease Severity – 43
    • Uceris Patient ‘Typical’ Treatment History – 44
    • Uceris Patient: ‘Typical’ Lifestyle – 45
    • Uceris Patient: ‘Typical’ Treatment Adherence – 46
    • Uceris Patient: ‘Typical’ Comorbidities – 47
    Xeljanz Patient Profile – 48
    • Xeljanz ‘Typical’ Patient Summary – 49
    • Xeljanz Patient ‘Typical’ Disease Severity – 50
    • Xeljanz Patient ‘Typical’ Treatment History – 51
    • Xeljanz Patient: ‘Typical’ Lifestyle – 52
    • Xeljanz Patient: ‘Typical’ Treatment Adherence – 53
    • Xeljanz Patient: ‘Typical’ Comorbidities – 54
    Zeposia Patient Profile – 55
    • Zeposia ‘Typical’ Patient Summary – 56
    • Zeposia Patient ‘Typical’ Disease Severity – 57
    • Zeposia Patient ‘Typical’ Treatment History – 58
    • Zeposia Patient: ‘Typical’ Lifestyle – 59
    • Zeposia Patient: ‘Typical’ Treatment Adherence – 60
    • Zeposia Patient: ‘Typical’ Comorbidities – 61
    Simponi Patient Profile – 62
    • Simponi ‘Typical’ Patient Summary – 63
    • Simponi Patient ‘Typical’ Disease Severity – 64
    • Simponi Patient ‘Typical’ Treatment History – 65
    • Simponi Patient: ‘Typical’ Lifestyle – 66
    • Simponi Patient: ‘Typical’ Treatment Adherence – 67
    • Simponi Patient: ‘Typical’ Comorbidities – 68
UC Prescription Trends in Patient Sub-groups – 69
    UC Prescription Trends by Disease Severity – 70
    • Disease Severity: Mild Patient Trends – 71
    • Disease Severity: Mild to Moderate Patient Trends – 72
    • Disease Severity: Moderate Patient Trends – 73
    • Disease Severity: Moderate to Severe Patient Trends – 74
    • Disease Severity: Severe Patient Trends – 75
    UC Prescription Trends by Treatment History – 76
    • Treatment History: Biologic Naïve – 77
    • Treatment History: Failed One Biologic – 78
    • Treatment History: Failed Two Biologics – 79
    • Treatment History: Failed Three or More Biologics – 80
    UC Prescription Trends by Lifestyle – 81
    • Lifestyle: Very Active and Busy – 82
    • Lifestyle: Moderately Active – 83
    • Lifestyle: Less Active or Sedentary – 84
    UC Prescription Trends by Treatment Adherence – 85
    • Treatment Adherence: Strong Compliance with Treatment – 86
    • Treatment Adherence: Moderate Compliance with Treatment – 87
    • Treatment Adherence: Poor Compliance with Treatment – 88
    • Rx Trends by Comorbidities – 89
    • Comorbidities: Good Health with Few or No Comorbidities – 90
    • Comorbidities: Moderate Health with Some Comorbidities – 91
    • Comorbidities: Poor Health with Multiple Comorbidities – 92
Contact – 93
 
Contact Our UC Strategist
Elio Evangelista elio.evangelista@vivisumpartners.com 919-428-6478  

Complete the form below for a sample of this research.

Name
Newsletter signup